FDCC
CABA icon

Foster Dykema Cabot & Co’s Cabaletta Bio CABA Stock Holding History

Foster Dykema Cabot & Co’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-309
Closed -$4K – 337
2023
Q2 		$4K Buy
+309
New +$3.35K ﹤0.01% 314

Other funds holding CABA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foster Dykema Cabot & Co's CABA Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Cabaletta Bio (CABA) in Q3 2023, closing a stake of 309 shares — an estimated $4K sold.

Foster Dykema Cabot & Co first reported a position in CABA in Q2 2023 and held it in 1 quarter. The position peaked at $4K in Q2 2023. 97 funds tracked by Wall St. Rank hold CABA as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Cabaletta Bio position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 309 Cabaletta Bio shares in Q3 2023, an estimated $4K.
  • Foster Dykema Cabot & Co first reported a position in Cabaletta Bio in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Cabaletta Bio position peaked at $4K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.